Superlymph 25 IU 20 pcs vaginal and rectal suppositories

Indications

In the comprehensive treatment of herpetic diseases of the urogenital tract, including those complicated by bacterial and other viral infections.
In the comprehensive treatment of chronic recurrent uncomplicated cystitis to prolong the remission period.

Method of application and doses

Before administration, remove the packaging material from the suppository. For the treatment of viral infection in the acute stage, the drug Superlimf® 10 IU/25 IU is used vaginally or rectally depending on the patient's gender, if necessary alternating the method of administration, Superlimf® 25 IU at 1 suppository once a day or Superlimf® 10 IU at 1 suppository twice a day in the morning and evening.

The duration of the course is from 10 to 20 days.

For the prevention of recurrence of viral infection, the drug Superlimf® 10 IU is used at 1 suppository once a day, with the possibility of alternating rectal and vaginal administration.

The duration of the course is 10 days.

To prevent possible recurrences, repeated courses are allowed sequentially or after 1-2 months.

In the complex therapy of chronic recurrent uncomplicated cystitis to extend the remission period, the drug Superlimf® 25 IU is used rectally at 1 suppository once a day for 10 days. The course of therapy with Superlimf® 25 IU is started simultaneously with antibacterial and symptomatic therapy of the cystitis episode in patients.

Use the drug according to the method of application and in the doses specified in the instructions. If necessary, please consult a doctor before using the medication.

Side effects

Adverse reactions listed below are categorized according to the affected organs and systems and frequency of occurrence. The frequency of occurrence is defined as follows: very often (>1/10), often (>1/100 and 1/1000 and 1/10000 and

Section: Composition

One suppository contains:
Active ingredient: protein-peptide complex from pig blood leukocytes Superlimf® substance-powder 10 IU / 25 IU. Excipients: cocoa butter (cocoa seed fat), anhydrous lanolin.

Description of the dosage form

Suppositories from white to light yellow in color, cylindrical or torpedo-shaped. Heterogeneity in the form of inclusions or marbling is allowed, as well as the presence of an air core and a funnel-shaped indentation.

• Increased sensitivity to porcine proteins and excipients;

• Body temperature above 38 °C;

• Severe allergic reactions in history;

• Malignant neoplasms in the active stage;

• Breastfeeding period. Age under 18 years (due to lack of data on efficacy and safety)

The drug is unsuitable for use if:

• the integrity of the packaging is compromised;

• the labeling is missing;

• the physical properties of the drug have changed (change in color, appearance of the smell of rancid fat, deformation of the suppository).

The excipients in the Superlimf'0 drug contain lanolin, which may cause local skin reactions (e.g., contact dermatitis).

Overdose

Cases of drug overdose have not been reported.

Interaction

Interaction studies have not been conducted. If you are taking other medications (including over-the-counter) before using the Superlimf* 10 IU/25 IU, consult your doctor.

Section: Pharmacodynamics

Characteristic: The substance Superlimf® is a protein-peptide complex with a molecular weight of less than 40,000 Da and the activity of a number of cytokines, including the factor that inhibits macrophage migration, obtained in a continuous production cycle from cultures of leukocytes from pig blood, which are cultivated in a colorless medium 199. No excipients are used in the lyophilization process.

Superlimf® is an immunomodulator, representing a natural complex of natural antimicrobial peptides and cytokines - universal stimulators of the immune system with the activity of the factor that inhibits macrophage migration, interleukin 1 (IL-1), IL-6, tumor necrosis factor (TNF), transforming growth factor, secreted by leukocytes of peripheral pig blood.

It has antiviral, antimicrobial, and antifungal effects. The drug stimulates the functional activity of phagocytic cells (monocytes and neutrophils): activates phagocytosis, cytokine production (IL-1, TNF), induces antitumor cytotoxicity of macrophages, regulates the migration of cells to the site of inflammation, and increases the activity of natural killers. The drug has antioxidant activity, reduces the development of inflammatory reactions, and stimulates regeneration and epithelialization of wound defects.

Pharmacokinetics

With intravaginal administration, the systemic bioavailability is minimal.